US Broker Ratings

Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: Exploring a Potential 55% Upside in the Biotech Sector

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is capturing the attention of investors with its promising prospects in the biotechnology sector. With a market capitalization of $1.93 billion, this U.S.-based biopharmaceutical company..

CG Oncology, Inc. (CGON) Stock Analysis: Exploring a 132% Potential Upside in the Biotechnology Sector

Investors are often on the lookout for compelling opportunities in the healthcare sector, and CG Oncology, Inc. (NASDAQ: CGON) presents an intriguing case. As a biotechnology company with a market..

Progyny, Inc. (PGNY) Stock Analysis: Exploring a 19.32% Potential Upside in the Growing Fertility Benefits Sector

Progyny, Inc. (NASDAQ: PGNY) stands at the intersection of healthcare innovation and employee benefits, offering a unique value proposition within the fertility and family-building sector. As an essential player in..

PROCEPT BioRobotics (PRCT) Stock Analysis: A 33% Upside Potential in the Medical Device Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a rising star in the healthcare sector, operates at the intersection of medical devices and robotics. With a market capitalization of $3.19 billion, this San..

Certara, Inc. (CERT) Stock Analysis: Exploring a 34.85% Potential Upside

Certara, Inc. (NASDAQ: CERT) stands at the forefront of the healthcare sector, specializing in health information services. With a market capitalization of $1.9 billion, Certara provides cutting-edge technology-enabled services and..

Vericel Corporation (VCEL): Analyst Consensus Favors ‘Buy’ with 39.54% Potential Upside

Vericel Corporation (NASDAQ: VCEL), a prominent player in the biopharmaceutical sector, has captured the attention of investors with its notable growth potential and strong analyst consensus. With a market capitalization..

Recursion Pharmaceuticals (RXRX) Stock Analysis: Navigating the 41.16% Potential Upside Amidst a Biotech Revolution

Recursion Pharmaceuticals, Inc. (RXRX), a pioneering force in the biotechnology sector, is capturing investor attention with its robust pipeline of drug discovery and a potential upside of 41.16%. Headquartered in..

Belite Bio, Inc (BLTE) Stock Analysis: A 47% Upside Potential for This Biotech Innovator

For individual investors with an eye on the healthcare sector, Belite Bio, Inc (NASDAQ: BLTE) presents an intriguing opportunity in the biotechnology industry. With a robust market capitalization of $1.88..

Kymera Therapeutics (KYMR) Stock Analysis: A Healthcare Innovator with Nearly 40% Upside Potential

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a compelling player in the biotechnology sector, commanding attention with its innovative approach to drug development and promising growth prospects. Headquartered in Watertown, Massachusetts,..

Viking Therapeutics, Inc. (VKTX) Investor Outlook: Assessing a 240% Upside Potential

Viking Therapeutics, Inc. (NASDAQ: VKTX) stands out in the biotechnology sector with a remarkable potential upside of 240.62% according to analyst ratings. This company, headquartered in San Diego, California, is..

Envista Holdings Corporation (NVST) Stock Analysis: Navigating Challenges in the Dental Products Market

Envista Holdings Corporation (NYSE: NVST), a prominent player in the healthcare sector specializing in medical instruments and supplies, is navigating a complex landscape in the dental products market. As of..

Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Unveiling 104% Potential Upside in Biotechnology

For investors with an eye on the biotechnology sector, Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) presents a compelling opportunity. With a market capitalization of $2.18 billion, Apellis is a commercial-stage biopharmaceutical..

QuidelOrtho Corporation (QDEL) Investor Outlook: Exploring a 63.58% Upside Potential in Healthcare Diagnostics

QuidelOrtho Corporation (QDEL), a notable player in the healthcare sector, specifically within the medical devices industry, presents an intriguing case for investors seeking opportunities in diagnostic testing solutions. Headquartered in..

NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a Potential 142% Upside in the Biotech Sector

NewAmsterdam Pharma Company N.V. (NAMS), a promising player in the biotechnology sector, has been turning heads in the investment community with its impressive growth potential and strategic focus on groundbreaking..

Premier, Inc. (PINC) Stock Analysis: A Healthcare Giant with a 3.83% Dividend Yield

Premier, Inc. (NASDAQ: PINC) stands as a pivotal player in the healthcare sector, specifically within the health information services industry. Headquartered in Charlotte, North Carolina, this American company is dedicated..

Addus HomeCare Corporation (ADUS) Stock Analysis: Exploring an 18.46% Upside Potential

Addus HomeCare Corporation (NASDAQ: ADUS), a key player in the healthcare sector, continues to capture investor attention with its robust growth metrics and a promising upside potential. Headquartered in Frisco,..

Select Medical Holdings Corpora (SEM)

⚠️ No article content returned.

..

HUTCHMED (China) Limited (HCM) Investor Outlook: Exploring a 67.55% Potential Upside

HUTCHMED (China) Limited (NASDAQ: HCM) stands out in the healthcare sector with its focus on developing targeted therapeutics and immunotherapies for cancer and immunological diseases. Based in Hong Kong, this..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: Unpacking a 30% Upside Potential in the Healthcare Sector

Alignment Healthcare, Inc. (NASDAQ: ALHC) is capturing the attention of investors with a tantalizing 30.16% potential upside, making it a noteworthy contender in the healthcare sector. Based in Orange, California,..

LivaNova PLC (LIVN) Stock Analysis: A 35.56% Upside Potential Amid Strong Buy Ratings

LivaNova PLC (NASDAQ: LIVN), a prominent player in the healthcare sector specializing in medical devices, is currently capturing the attention of investors with its promising growth prospects and robust analyst..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds